

Table D - Injection Summary of Active Participants by Visit and Site

	Overall	Bronx Prevention Center CRS Site ID 253	New Jersey Medical School CRS Site ID 254	Emavundleni CRS Site ID 255	Spilhaus CRS Site ID 256
Week 4 (Injection 1)					
Number of Evaluated Participants	122	18	15	38	51
Number of Active Participants	122	18	15	38	51
Number of Terminated Participants	0	0	0	0	0
Injection Received by Active Participants					
Yes	120/122 (98.4%)	18/18 (100.0%)	15/15 (100.0%)	36/38 (94.7%)	51/51 (100.0%)
No	2/122 (1.6%)	0/18 (0.0%)	0/15 (0.0%)	2/38 (5.3%)	0/51 (0.0%)
Reasons Not Received by Active Participants					
Participant Missed Injection Window	0/2 (0.0%)	-	-	0/2 (0.0%)	-
Participant Missed Injection Visit	0/2 (0.0%)	-	-	0/2 (0.0%)	-
Injection Schedule Permanently Discontinued	1/2 (50.0%)	-	-	1/2 (50.0%)	-
Unknown Reason	1/2 (50.0%)	-	-	1/2 (50.0%)	-
Reasons For Product Hold					
Missing	0/1 (0.0%)	-	-	0/1 (0.0%)	-
NA	0/1 (0.0%)	-	-	0/1 (0.0%)	-
product related toxicity	0/1 (0.0%)	-	-	0/1 (0.0%)	-
abnormal lab value	0/1 (0.0%)	-	-	0/1 (0.0%)	-
clinical reasons	0/1 (0.0%)	-	-	0/1 (0.0%)	-
Hep B infection	0/1 (0.0%)	-	-	0/1 (0.0%)	-
QTcF > 500 ms or increase	0/1 (0.0%)	-	-	0/1 (0.0%)	-
HIV infection suspected	0/1 (0.0%)	-	-	0/1 (0.0%)	-
pregnancy/breastfeeding	0/1 (0.0%)	-	-	0/1 (0.0%)	-
use of prohibited con med	0/1 (0.0%)	-	-	0/1 (0.0%)	-
request by Ppt	0/1 (0.0%)	-	-	0/1 (0.0%)	-
Ppt unwilling/unable to comply w/procedu	0/1 (0.0%)	-	-	0/1 (0.0%)	-
Ppt unwilling/unable to attend visit w/i	0/1 (0.0%)	-	-	0/1 (0.0%)	-
PPT planning to use PrEP or PEP	0/1 (0.0%)	-	-	0/1 (0.0%)	-
other, specify	1/1 (100.0%)	-	-	1/1 (100.0%)	-

¹Evaluated number of participants includes those whose visit window has closed, plus any participants that have completed the visit even though their visit window has not yet closed.

²Active participants includes those who have been evaluated (as above) and have either completed the visit or have missed it without terminating from the study.

Table D - Injection Summary of Active Participants by Visit and Site

	Overall	Bronx Prevention Center CRS Site ID 253	New Jersey Medical School CRS Site ID 254	Emavundleni CRS Site ID 255	Spilhaus CRS Site ID 256
Week 12 (Injection 2)					
Number of Evaluated Participants	122	18	15	38	51
Number of Active Participants	122	18	15	38	51
Number of Terminated Participants	0	0	0	0	0
Injection Received by Active Participants					
No	9/122 (7.4%)	0/18 (0.0%)	2/15 (13.3%)	3/38 (7.9%)	4/51 (7.8%)
Yes	113/122 (92.6%)	18/18 (100.0%)	13/15 (86.7%)	35/38 (92.1%)	47/51 (92.2%)
Reasons Not Received by Active Participants					
Participant Missed Injection Window	1/9 (11.1%)	-	0/2 (0.0%)	1/3 (33.3%)	0/4 (0.0%)
Participant Missed Injection Visit	1/9 (11.1%)	-	0/2 (0.0%)	1/3 (33.3%)	0/4 (0.0%)
Injection Schedule Permanently Discontinued	7/9 (77.8%)	-	2/2 (100.0%)	1/3 (33.3%)	4/4 (100.0%)
Unknown Reason	0/9 (0.0%)	-	0/2 (0.0%)	0/3 (0.0%)	0/4 (0.0%)
Reasons For Missing Visit					
Missing	0/1 (0.0%)	-	-	0/1 (0.0%)	-
NA	0/1 (0.0%)	-	-	0/1 (0.0%)	-
unable to contact ppt	1/1 (100.0%)	-	-	1/1 (100.0%)	-
unable to schedule appts.	0/1 (0.0%)	-	-	0/1 (0.0%)	-
participant refused visit	0/1 (0.0%)	-	-	0/1 (0.0%)	-
participant incarcerated	0/1 (0.0%)	-	-	0/1 (0.0%)	-
ppt. admit to health facility	0/1 (0.0%)	-	-	0/1 (0.0%)	-
participant withdrew	0/1 (0.0%)	-	-	0/1 (0.0%)	-
participant deceased	0/1 (0.0%)	-	-	0/1 (0.0%)	-
other, specify	0/1 (0.0%)	-	-	0/1 (0.0%)	-
Reasons For Product Hold					
Missing	0/7 (0.0%)	-	0/2 (0.0%)	0/1 (0.0%)	0/4 (0.0%)
NA	0/7 (0.0%)	-	0/2 (0.0%)	0/1 (0.0%)	0/4 (0.0%)
product related toxicity	1/7 (14.3%)	-	0/2 (0.0%)	1/1 (100.0%)	0/4 (0.0%)
abnormal lab value	3/7 (42.9%)	-	0/2 (0.0%)	0/1 (0.0%)	3/4 (75.0%)
clinical reasons	0/7 (0.0%)	-	0/2 (0.0%)	0/1 (0.0%)	0/4 (0.0%)
Hep B infection	0/7 (0.0%)	-	0/2 (0.0%)	0/1 (0.0%)	0/4 (0.0%)
QTcF > 500 ms or increase	0/7 (0.0%)	-	0/2 (0.0%)	0/1 (0.0%)	0/4 (0.0%)
HIV infection suspected	0/7 (0.0%)	-	0/2 (0.0%)	0/1 (0.0%)	0/4 (0.0%)
pregnancy/breastfeeding	1/7 (14.3%)	-	1/2 (50.0%)	0/1 (0.0%)	0/4 (0.0%)
use of prohibited con med	0/7 (0.0%)	-	0/2 (0.0%)	0/1 (0.0%)	0/4 (0.0%)

¹Evaluated number of participants includes those whose visit window has closed, plus any participants that have completed the visit even though their visit window has not yet closed.

²Active participants includes those who have been evaluated (as above) and have either completed the visit or have missed it without terminating from the study.

Table D - Injection Summary of Active Participants by Visit and Site

	Overall	Bronx Prevention Center CRS Site ID 253	New Jersey Medical School CRS Site ID 254	Emavundleni CRS Site ID 255	Spilhaus CRS Site ID 256
request by Ppt	0/7 (0.0%)	-	0/2 (0.0%)	0/1 (0.0%)	0/4 (0.0%)
Ppt unwilling/unable to comply w/procedu	0/7 (0.0%)	-	0/2 (0.0%)	0/1 (0.0%)	0/4 (0.0%)
Ppt unwilling/unable to attend visit w/i	1/7 (14.3%)	-	1/2 (50.0%)	0/1 (0.0%)	0/4 (0.0%)
PPt planning to use PrEP or PEP	0/7 (0.0%)	-	0/2 (0.0%)	0/1 (0.0%)	0/4 (0.0%)
other, specify	1/7 (14.3%)	-	0/2 (0.0%)	0/1 (0.0%)	1/4 (25.0%)

¹Evaluated number of participants includes those whose visit window has closed, plus any participants that have completed the visit even though their visit window has not yet closed.

²Active participants includes those who have been evaluated (as above) and have either completed the visit or have missed it without terminating from the study.

Table D - Injection Summary of Active Participants by Visit and Site

	Overall	Bronx Prevention Center CRS Site ID 253	New Jersey Medical School CRS Site ID 254	Emavundleni CRS Site ID 255	Spilhaus CRS Site ID 256
Week 20 (Injection 3)					
Number of Evaluated Participants	122	18	15	38	51
Number of Active Participants	122	18	15	38	51
Number of Terminated Participants	0	0	0	0	0
Injection Received by Active Participants					
No	10/122 (8.2%)	0/18 (0.0%)	3/15 (20.0%)	4/38 (10.5%)	3/51 (5.9%)
Yes	112/122 (91.8%)	18/18 (100.0%)	12/15 (80.0%)	34/38 (89.5%)	48/51 (94.1%)
Reasons Not Received by Active Participants					
Participant Missed Injection Window	1/10 (10.0%)	-	1/3 (33.3%)	0/4 (0.0%)	0/3 (0.0%)
Participant Missed Injection Visit	2/10 (20.0%)	-	0/3 (0.0%)	2/4 (50.0%)	0/3 (0.0%)
Injection Schedule Permanently Discontinued	7/10 (70.0%)	-	2/3 (66.7%)	2/4 (50.0%)	3/3 (100.0%)
Unknown Reason	0/10 (0.0%)	-	0/3 (0.0%)	0/4 (0.0%)	0/3 (0.0%)
Reasons For Missing Visit					
Missing	0/2 (0.0%)	-	-	0/2 (0.0%)	-
NA	0/2 (0.0%)	-	-	0/2 (0.0%)	-
unable to contact ppt	0/2 (0.0%)	-	-	0/2 (0.0%)	-
unable to schedule appts.	1/2 (50.0%)	-	-	1/2 (50.0%)	-
participant refused visit	0/2 (0.0%)	-	-	0/2 (0.0%)	-
participant incarcerated	0/2 (0.0%)	-	-	0/2 (0.0%)	-
ppt. admit to health facility	0/2 (0.0%)	-	-	0/2 (0.0%)	-
participant withdrew	1/2 (50.0%)	-	-	1/2 (50.0%)	-
participant deceased	0/2 (0.0%)	-	-	0/2 (0.0%)	-
other, specify	0/2 (0.0%)	-	-	0/2 (0.0%)	-
Reasons For Product Hold					
Missing	0/7 (0.0%)	-	0/2 (0.0%)	0/2 (0.0%)	0/3 (0.0%)
NA	0/7 (0.0%)	-	0/2 (0.0%)	0/2 (0.0%)	0/3 (0.0%)
product related toxicity	1/7 (14.3%)	-	0/2 (0.0%)	1/2 (50.0%)	0/3 (0.0%)
abnormal lab value	3/7 (42.9%)	-	0/2 (0.0%)	0/2 (0.0%)	3/3 (100.0%)
clinical reasons	0/7 (0.0%)	-	0/2 (0.0%)	0/2 (0.0%)	0/3 (0.0%)
Hep B infection	0/7 (0.0%)	-	0/2 (0.0%)	0/2 (0.0%)	0/3 (0.0%)
QTcF > 500 ms or increase	0/7 (0.0%)	-	0/2 (0.0%)	0/2 (0.0%)	0/3 (0.0%)
HIV infection suspected	1/7 (14.3%)	-	0/2 (0.0%)	1/2 (50.0%)	0/3 (0.0%)
pregnancy/breastfeeding	1/7 (14.3%)	-	1/2 (50.0%)	0/2 (0.0%)	0/3 (0.0%)
use of prohibited con med	0/7 (0.0%)	-	0/2 (0.0%)	0/2 (0.0%)	0/3 (0.0%)

¹Evaluated number of participants includes those whose visit window has closed, plus any participants that have completed the visit even though their visit window has not yet closed.

²Active participants includes those who have been evaluated (as above) and have either completed the visit or have missed it without terminating from the study.

HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre Exposure Prophylaxis (PrEP)
Report January 17, 2018
Visit Cutoff Date: January 16, 2018

Table D - Injection Summary of Active Participants by Visit and Site

	Overall	Bronx Prevention Center CRS Site ID 253	New Jersey Medical School CRS Site ID 254	Emavundleni CRS Site ID 255	Spilhaus CRS Site ID 256
request by Ppt	0/7 (0.0%)	-	0/2 (0.0%)	0/2 (0.0%)	0/3 (0.0%)
Ppt unwilling/unable to comply w/procedu	0/7 (0.0%)	-	0/2 (0.0%)	0/2 (0.0%)	0/3 (0.0%)
Ppt unwilling/unable to attend visit w/i	1/7 (14.3%)	-	1/2 (50.0%)	0/2 (0.0%)	0/3 (0.0%)
PPt planning to use PrEP or PEP	0/7 (0.0%)	-	0/2 (0.0%)	0/2 (0.0%)	0/3 (0.0%)
other, specify	0/7 (0.0%)	-	0/2 (0.0%)	0/2 (0.0%)	0/3 (0.0%)

¹Evaluated number of participants includes those whose visit window has closed, plus any participants that have completed the visit even though their visit window has not yet closed.

²Active participants includes those who have been evaluated (as above) and have either completed the visit or have missed it without terminating from the study.

Table D - Injection Summary of Active Participants by Visit and Site

	Overall	Bronx Prevention Center CRS Site ID 253	New Jersey Medical School CRS Site ID 254	Emavundleni CRS Site ID 255	Spilhaus CRS Site ID 256
Week 28 (Injection 4)					
Number of Evaluated Participants	122	18	15	38	51
Number of Active Participants	121	18	15	37	51
Number of Terminated Participants	1	0	0	1	0
Injection Received by Active Participants					
Yes	110/121 (90.9%)	18/18 (100.0%)	12/15 (80.0%)	34/37 (91.9%)	46/51 (90.2%)
No	11/121 (9.1%)	0/18 (0.0%)	3/15 (20.0%)	3/37 (8.1%)	5/51 (9.8%)
Reasons Not Received by Active Participants					
Participant Missed Injection Window	1/11 (9.1%)	-	0/3 (0.0%)	1/3 (33.3%)	0/5 (0.0%)
Participant Missed Injection Visit	0/11 (0.0%)	-	0/3 (0.0%)	0/3 (0.0%)	0/5 (0.0%)
Injection Schedule Permanently Discontinued	10/11 (90.9%)	-	3/3 (100.0%)	2/3 (66.7%)	5/5 (100.0%)
Unknown Reason	0/11 (0.0%)	-	0/3 (0.0%)	0/3 (0.0%)	0/5 (0.0%)
Reasons For Product Hold					
Missing	0/10 (0.0%)	-	0/3 (0.0%)	0/2 (0.0%)	0/5 (0.0%)
NA	0/10 (0.0%)	-	0/3 (0.0%)	0/2 (0.0%)	0/5 (0.0%)
product related toxicity	1/10 (10.0%)	-	0/3 (0.0%)	1/2 (50.0%)	0/5 (0.0%)
abnormal lab value	3/10 (30.0%)	-	0/3 (0.0%)	0/2 (0.0%)	3/5 (60.0%)
clinical reasons	1/10 (10.0%)	-	1/3 (33.3%)	0/2 (0.0%)	0/5 (0.0%)
Hep B infection	0/10 (0.0%)	-	0/3 (0.0%)	0/2 (0.0%)	0/5 (0.0%)
QTcF > 500 ms or increase	0/10 (0.0%)	-	0/3 (0.0%)	0/2 (0.0%)	0/5 (0.0%)
HIV infection suspected	1/10 (10.0%)	-	0/3 (0.0%)	1/2 (50.0%)	0/5 (0.0%)
pregnancy/breastfeeding	1/10 (10.0%)	-	1/3 (33.3%)	0/2 (0.0%)	0/5 (0.0%)
use of prohibited con med	0/10 (0.0%)	-	0/3 (0.0%)	0/2 (0.0%)	0/5 (0.0%)
request by Ppt	0/10 (0.0%)	-	0/3 (0.0%)	0/2 (0.0%)	0/5 (0.0%)
Ppt unwilling/unable to comply w/procedu	1/10 (10.0%)	-	0/3 (0.0%)	0/2 (0.0%)	1/5 (20.0%)
Ppt unwilling/unable to attend visit w/i	1/10 (10.0%)	-	1/3 (33.3%)	0/2 (0.0%)	0/5 (0.0%)
PPt planning to use PrEP or PEP	0/10 (0.0%)	-	0/3 (0.0%)	0/2 (0.0%)	0/5 (0.0%)
other, specify	1/10 (10.0%)	-	0/3 (0.0%)	0/2 (0.0%)	1/5 (20.0%)

¹Evaluated number of participants includes those whose visit window has closed, plus any participants that have completed the visit even though their visit window has not yet closed.

²Active participants includes those who have been evaluated (as above) and have either completed the visit or have missed it without terminating from the study.

Table D - Injection Summary of Active Participants by Visit and Site

	Overall	Bronx Prevention Center CRS Site ID 253	New Jersey Medical School CRS Site ID 254	Emavundleni CRS Site ID 255	Spilhaus CRS Site ID 256
Week 36 (Injection 5)					
Number of Evaluated Participants	122	18	15	38	51
Number of Active Participants	121	18	15	37	51
Number of Terminated Participants	1	0	0	1	0
Injection Received by Active Participants					
No	15/121 (12.4%)	0/18 (0.0%)	3/15 (20.0%)	6/37 (16.2%)	6/51 (11.8%)
Yes	106/121 (87.6%)	18/18 (100.0%)	12/15 (80.0%)	31/37 (83.8%)	45/51 (88.2%)
Reasons Not Received by Active Participants					
Participant Missed Injection Window	0/15 (0.0%)	-	0/3 (0.0%)	0/6 (0.0%)	0/6 (0.0%)
Participant Missed Injection Visit	1/15 (6.7%)	-	0/3 (0.0%)	1/6 (16.7%)	0/6 (0.0%)
Injection Schedule Permanently Discontinued	14/15 (93.3%)	-	3/3 (100.0%)	5/6 (83.3%)	6/6 (100.0%)
Unknown Reason	0/15 (0.0%)	-	0/3 (0.0%)	0/6 (0.0%)	0/6 (0.0%)
Reasons For Missing Visit					
Missing	1/2 (50.0%)	-	1/1 (100.0%)	0/1 (0.0%)	-
NA	0/2 (0.0%)	-	0/1 (0.0%)	0/1 (0.0%)	-
unable to contact ppt	1/2 (50.0%)	-	0/1 (0.0%)	1/1 (100.0%)	-
unable to schedule appts.	0/2 (0.0%)	-	0/1 (0.0%)	0/1 (0.0%)	-
participant refused visit	0/2 (0.0%)	-	0/1 (0.0%)	0/1 (0.0%)	-
participant incarcerated	0/2 (0.0%)	-	0/1 (0.0%)	0/1 (0.0%)	-
ppt. admit to health facility	0/2 (0.0%)	-	0/1 (0.0%)	0/1 (0.0%)	-
participant withdrew	0/2 (0.0%)	-	0/1 (0.0%)	0/1 (0.0%)	-
participant deceased	0/2 (0.0%)	-	0/1 (0.0%)	0/1 (0.0%)	-
other, specify	0/2 (0.0%)	-	0/1 (0.0%)	0/1 (0.0%)	-
Reasons For Product Hold					
Missing	0/14 (0.0%)	-	0/3 (0.0%)	0/5 (0.0%)	0/6 (0.0%)
NA	0/14 (0.0%)	-	0/3 (0.0%)	0/5 (0.0%)	0/6 (0.0%)
product related toxicity	1/14 (7.1%)	-	0/3 (0.0%)	1/5 (20.0%)	0/6 (0.0%)
abnormal lab value	6/14 (42.9%)	-	0/3 (0.0%)	2/5 (40.0%)	4/6 (66.7%)
clinical reasons	1/14 (7.1%)	-	1/3 (33.3%)	0/5 (0.0%)	0/6 (0.0%)
Hep B infection	0/14 (0.0%)	-	0/3 (0.0%)	0/5 (0.0%)	0/6 (0.0%)
QTcF > 500 ms or increase	1/14 (7.1%)	-	0/3 (0.0%)	1/5 (20.0%)	0/6 (0.0%)
HIV infection suspected	2/14 (14.3%)	-	0/3 (0.0%)	1/5 (20.0%)	1/6 (16.7%)
pregnancy/breastfeeding	1/14 (7.1%)	-	1/3 (33.3%)	0/5 (0.0%)	0/6 (0.0%)
use of prohibited con med	0/14 (0.0%)	-	0/3 (0.0%)	0/5 (0.0%)	0/6 (0.0%)

¹Evaluated number of participants includes those whose visit window has closed, plus any participants that have completed the visit even though their visit window has not yet closed.

²Active participants includes those who have been evaluated (as above) and have either completed the visit or have missed it without terminating from the study.

HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre Exposure Prophylaxis (PrEP)
Report January 17, 2018
Visit Cutoff Date: January 16, 2018

Table D - Injection Summary of Active Participants by Visit and Site

	Overall	Bronx Prevention Center CRS Site ID 253	New Jersey Medical School CRS Site ID 254	Emavundleni CRS Site ID 255	Spilhaus CRS Site ID 256
request by Ppt	0/14 (0.0%)	-	0/3 (0.0%)	0/5 (0.0%)	0/6 (0.0%)
Ppt unwilling/unable to comply w/procedu	1/14 (7.1%)	-	0/3 (0.0%)	0/5 (0.0%)	1/6 (16.7%)
Ppt unwilling/unable to attend visit w/i	1/14 (7.1%)	-	1/3 (33.3%)	0/5 (0.0%)	0/6 (0.0%)
PPt planning to use PrEP or PEP	0/14 (0.0%)	-	0/3 (0.0%)	0/5 (0.0%)	0/6 (0.0%)
other, specify	0/14 (0.0%)	-	0/3 (0.0%)	0/5 (0.0%)	0/6 (0.0%)

¹Evaluated number of participants includes those whose visit window has closed, plus any participants that have completed the visit even though their visit window has not yet closed.

²Active participants includes those who have been evaluated (as above) and have either completed the visit or have missed it without terminating from the study.

Table D - Injection Summary of Active Participants by Visit and Site

	Overall	Bronx Prevention Center CRS Site ID 253	New Jersey Medical School CRS Site ID 254	Emavundleni CRS Site ID 255	Spilhaus CRS Site ID 256
Week 44 (Injection 6)					
Number of Evaluated Participants	122	18	15	38	51
Number of Active Participants	121	18	15	37	51
Number of Terminated Participants	1	0	0	1	0
Injection Received by Active Participants					
No	15/121 (12.4%)	0/18 (0.0%)	2/15 (13.3%)	7/37 (18.9%)	6/51 (11.8%)
Yes	106/121 (87.6%)	18/18 (100.0%)	13/15 (86.7%)	30/37 (81.1%)	45/51 (88.2%)
Reasons Not Received by Active Participants					
Participant Missed Injection Window	1/15 (6.7%)	-	0/2 (0.0%)	1/7 (14.3%)	0/6 (0.0%)
Participant Missed Injection Visit	1/15 (6.7%)	-	0/2 (0.0%)	1/7 (14.3%)	0/6 (0.0%)
Injection Schedule Permanently Discontinued	13/15 (86.7%)	-	2/2 (100.0%)	5/7 (71.4%)	6/6 (100.0%)
Unknown Reason	0/15 (0.0%)	-	0/2 (0.0%)	0/7 (0.0%)	0/6 (0.0%)
Reasons For Missing Visit					
Missing	0/1 (0.0%)	-	-	0/1 (0.0%)	-
NA	0/1 (0.0%)	-	-	0/1 (0.0%)	-
unable to contact ppt	0/1 (0.0%)	-	-	0/1 (0.0%)	-
unable to schedule appts.	0/1 (0.0%)	-	-	0/1 (0.0%)	-
participant refused visit	0/1 (0.0%)	-	-	0/1 (0.0%)	-
participant incarcerated	0/1 (0.0%)	-	-	0/1 (0.0%)	-
ppt. admit to health facility	0/1 (0.0%)	-	-	0/1 (0.0%)	-
participant withdrew	0/1 (0.0%)	-	-	0/1 (0.0%)	-
participant deceased	0/1 (0.0%)	-	-	0/1 (0.0%)	-
other, specify	1/1 (100.0%)	-	-	1/1 (100.0%)	-
Reasons For Product Hold					
Missing	0/13 (0.0%)	-	0/2 (0.0%)	0/5 (0.0%)	0/6 (0.0%)
NA	0/13 (0.0%)	-	0/2 (0.0%)	0/5 (0.0%)	0/6 (0.0%)
product related toxicity	1/13 (7.7%)	-	0/2 (0.0%)	1/5 (20.0%)	0/6 (0.0%)
abnormal lab value	6/13 (46.2%)	-	0/2 (0.0%)	2/5 (40.0%)	4/6 (66.7%)
clinical reasons	0/13 (0.0%)	-	0/2 (0.0%)	0/5 (0.0%)	0/6 (0.0%)
Hep B infection	0/13 (0.0%)	-	0/2 (0.0%)	0/5 (0.0%)	0/6 (0.0%)
QTcF > 500 ms or increase	1/13 (7.7%)	-	0/2 (0.0%)	1/5 (20.0%)	0/6 (0.0%)
HIV infection suspected	2/13 (15.4%)	-	0/2 (0.0%)	1/5 (20.0%)	1/6 (16.7%)
pregnancy/breastfeeding	1/13 (7.7%)	-	1/2 (50.0%)	0/5 (0.0%)	0/6 (0.0%)
use of prohibited con med	0/13 (0.0%)	-	0/2 (0.0%)	0/5 (0.0%)	0/6 (0.0%)

¹Evaluated number of participants includes those whose visit window has closed, plus any participants that have completed the visit even though their visit window has not yet closed.

²Active participants includes those who have been evaluated (as above) and have either completed the visit or have missed it without terminating from the study.

Table D - Injection Summary of Active Participants by Visit and Site

	Overall	Bronx Prevention Center CRS Site ID 253	New Jersey Medical School CRS Site ID 254	Emavundleni CRS Site ID 255	Spilhaus CRS Site ID 256
request by Ppt	0/13 (0.0%)	-	0/2 (0.0%)	0/5 (0.0%)	0/6 (0.0%)
Ppt unwilling/unable to comply w/procedu	1/13 (7.7%)	-	0/2 (0.0%)	0/5 (0.0%)	1/6 (16.7%)
Ppt unwilling/unable to attend visit w/i	1/13 (7.7%)	-	1/2 (50.0%)	0/5 (0.0%)	0/6 (0.0%)
PPt planning to use PrEP or PEP	0/13 (0.0%)	-	0/2 (0.0%)	0/5 (0.0%)	0/6 (0.0%)
other, specify	0/13 (0.0%)	-	0/2 (0.0%)	0/5 (0.0%)	0/6 (0.0%)

¹Evaluated number of participants includes those whose visit window has closed, plus any participants that have completed the visit even though their visit window has not yet closed.

²Active participants includes those who have been evaluated (as above) and have either completed the visit or have missed it without terminating from the study.